Template for Reporting Results of Biomarker Testing of Specimens From Patients With Carcinoma of the Endometrium.

Authors Teri A. Longacre, MD, FCAP* Department of Pathology, Stanford Medicine, Stanford, CA Russell Broaddus, MD, PhD Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX Linus T. Chuang, MD Department of Obstetrics, Gynecology and Reproductive Science, Hess Center for Science and Medicine, Sinai Medical Center, New York, NY Michael B. Cohen, MD, FCAP Department of Pathology, Huntsman Cancer Hospital, Salt Lake City, UT Patricia Salter Jamieson, CTR University of Alabama at Birmingham, Birmingham, AL Elke A Jarboe, MD Department of Pathology, University of Utah, Salt Lake City, UT George L. Mutter, MD, FCAP Department of Pathology, Brigham and Women’s Hospital, Boston, MA Christopher N. Otis, MD, FCAP Department of Pathology, Baystate Medical Center, Springfield, MA Richard Zaino, MD, FCAP Department of Pathology, Penn State Hershey Medical Center, Hershey, PA

[1]  M. Dowsett,et al.  HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. , 2018, Journal of oncology practice.

[2]  A. Talhouk,et al.  Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.

[3]  E. Kuipers,et al.  Somatic aberrations of mismatch repair genes as a cause of microsatellite‐unstable cancers , 2014, The Journal of pathology.

[4]  W. Frankel,et al.  Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. , 2014, Gastroenterology.

[5]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[6]  Liang Cheng,et al.  Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach. , 2014, Human pathology.

[7]  Sharon Nofech-Mozes,et al.  Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. , 2014, Archives of pathology & laboratory medicine.

[8]  Donna M. Gress,et al.  Template for reporting results of biomarker testing of specimens from patients with carcinoma of the colon and rectum. , 2014, Archives of pathology & laboratory medicine.

[9]  A. Lazar,et al.  Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanoma , 2013, Cancer.

[10]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Rosenwald,et al.  Recent advances in de novo CD5+ diffuse large B cell lymphoma , 2013, American journal of hematology.

[12]  S. Leung,et al.  Histotype-Genotype Correlation in 36 High-grade Endometrial Carcinomas , 2013, The American journal of surgical pathology.

[13]  B. Bastian,et al.  Targeting activated KIT signaling for melanoma therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Medeiros,et al.  The Impact of MYC Rearrangements and “Double Hit” Abnormalities in Diffuse Large B-Cell Lymphoma , 2013, Current Hematologic Malignancy Reports.

[15]  W. Choi,et al.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.

[16]  K. Flaherty,et al.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[18]  W. Choi,et al.  CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.

[19]  S. O'toole,et al.  BRAF inhibitor activity in V600R metastatic melanoma. , 2013, European journal of cancer.

[20]  Robert N. Anderson,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels , 2013, Journal of the National Cancer Institute.

[21]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[23]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[24]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[25]  L. Medeiros,et al.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.

[26]  L. Staudt,et al.  BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab , 2011, Clinical Cancer Research.

[27]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[28]  C. Antonescu,et al.  KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.

[29]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[30]  Kai Fu,et al.  Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Gunn,et al.  Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity , 2010, BMC Cancer.

[32]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[33]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Kai Fu,et al.  A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy , 2009, Clinical Cancer Research.

[35]  Suet Yi Leung,et al.  Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1 , 2009, Nature Genetics.

[36]  I. Miura,et al.  Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.

[37]  L. Layfield,et al.  Effects of Fixative and Fixation Protocols on Assessment of Her-2/neu Oncogene Amplification Status by Fluorescence In Situ Hybridization , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[38]  B. Coiffier Treatment of diffuse large B-cell lymphoma. , 2005, Current hematology reports.

[39]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[40]  P. Tan,et al.  Effect of Fixation Period on HER2/neu Gene Amplification Detected by Fluorescence In Situ Hybridization in Invasive Breast Carcinoma , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  C. Jones,et al.  Routine Acid Decalcification of Bone Marrow Samples Can Preserve DNA for FISH and CGH Studies in Metastatic Prostate Cancer , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.